Psychedelics

Mydecine Innovations Group Appoints Josephine Wu to Board of Directors

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced the appointment of Josephine Wu, Founder and CIO at Aionious Management, Ltd., to the Company's Board of Directors.

Josh Bartch, Chairman and CEO of Mydecine, stated, "The Board of Directors welcomes Ms. Josephine Wu to our board as a contributing member as Mydecine continues its growth trajectory. Josephine's operational and financial leadership in the healthcare and biopharma spaces in addition to her experience bringing numerous successful drugs to market underpins Mydecine's core strategy in the sector. Her knowledge will be incredibly valuable as we continue to execute on our business model and provide tremendous value to our partners, investors and shareholders."

Ms. Wu has over 18 years of hedge fund, family office and global asset management experience including 10 years of listed, pre-IPO and early-stage Pan-Asia healthcare investment experience. She has been CIO and portfolio manager with combined assets under management over US$5 billion. She is the founder and CIO of Aionious Management Limited, a dedicated healthcare investment company which invests and provides business development and commercialization strategies in pan Asia region, specifically in China. Ms. Wu brings in an extensive network of experts in operation, clinical, market positioning and regulatory knowledge in the Pan Asia healthcare landscape. Her investments in different stages healthcare companies have led to a few successful commercialization launches of pharmaceutical products, regulatory approvals for decontamination solutions for hospitals and research centers and signing of strategic partnerships in commercialization transactions and IPOs.

"I am pleased to join Mydecine's Board of Directors to support management efforts to develop innovative solutions using psychedelic-assisted therapies to treat the global mental health challenge," said Ms. Wu. "Throughout my career, I have leveraged my experiences in healthcare to advance both start up and mature companies through their various stages of development. I am excited to get to assist Mydecine as it continues progress its business model."

Corporate Governance
Additionally, Mydecine, with its appointment of Ms. Wu continues to focus on best practices in corporate governance. As a result, OTC markets has removed the Caveat Emptor designation, which had previously been associated with its stock ticker. The Company continues to comply with all listing requirements of the OTC Markets and anticipates trading restrictions in the U.S. to be removed.

Further, the Company announces the resignation of Michael Connolly from the Board of Directors. The Company would like to thank Mr. Connolly for his time, services and for the valuable contributions he made during his tenure as Director. Ms. Wu replaced Mr. Connolly on the Board of Directors.

About Mydecine Innovations Group
Mydecine Innovations Group™ (CSE: MYCO) (OTC: MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company's world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.

At the heart of Mydecine's core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world's best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.

Learn more at: https://www.mydecine.com/ and follow us on Facebook , Twitter , and Instagram .

Mydecine Innovations Group Media Contacts:
Anne Donohoe / Nick Opich
KCSA Strategic Communications
adonohoe@kcsa.com / nopich@kcsa.com
1-212-896-1265 / 1-212-896-1206

On behalf of the Board of Directors:
Joshua Bartch, Chief Executive Officer
contact@mydecineinc.com

Corp Communication:
Charles Lee, Investor Relations
corp@mydecineinc.com
+1-720-277-9879

For further information about Mydecine Innovations Group, Inc., please visit the Company's profile on SEDAR at www.sedar.com or visit the Company's website at www.mydecine.com .

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, "will be", "looking forward" or variations of such words and phrases or statements that certain actions, events or results "will" occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Mydecine to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Mydecine will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)

COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

-

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Jefferies Healthcare Conference at 3:30 pm ET on June 8, 2023.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023

  • More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological support
  • Open label phase 2 study, conducted by Sunstone Therapies and scheduled to be presented at the ASCO annual meeting on June 5, is believed to be the longest clinical study of psilocybin ever conducted

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that new long-term efficacy data of investigational COMP360 psilocybin in cancer patients with major depressive disorder will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).

More than half of the patients (16/28) treated with a single dose of 25mg COMP360 psilocybin with psychological support remained in remission from their depression at 18 months post administration. The investigator-initiated study, led by Manish Agrawal, MD, at Sunstone Therapies , is believed to be the longest study of psilocybin therapy ever conducted.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences

Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in two upcoming healthcare conferences:

(PRNewsfoto/Seelos Therapeutics, Inc.)

  • the Benchmark Healthcare House Call Virtual Conference to be held on May 23 rd ; and
  • the 2023 Jefferies Global Healthcare Conference to be held in New York City , NY, on June 7-9, 2023 .

Seelos senior management will host one-on-one and small group meetings in the Benchmark Healthcare House Call Virtual Conference on May 23 rd .

To register for the Benchmark Healthcare House Call Virtual Conference, please visit here .

Raj Mehra, Ph.D., Chairman and CEO of Seelos, will present on Thursday, June 8 th at 9:00 AM ET at the Jefferies Global Healthcare Conference. Dr. Mehra and Seelos senior management will also host one-on-one meetings.

The Seelos presentation webcast at the 2023 Jefferies Global Healthcare Conference may be accessed here .

The 2023 Jefferies Global Healthcare Conference is an annual gathering of over 500 public & private healthcare companies and 3,000 leading executives, institutional investors, private equity investors & VCs, where attendees address near-term and long-term investment opportunities and discuss the current trends driving healthcare in the U.S. and internationally.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as early-stage programs in Huntington's disease, Alzheimer's disease, and Parkinson's disease.

For more information, please visit our website: http://seelostherapeutics.com , the content of which is not incorporated herein by reference.

Contact Information:

Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-two-upcoming-healthcare-conferences-301829907.html

SOURCE Seelos Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia

Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia

Distribution Agreement Grants Pentec Exclusive Distribution Rights for Altemia Lobe's Novel Sickle Cell Anemia Medical Food

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution agreement for the supply and distribution of Altemia™ with Pentec Health, Inc. ("Pentec Health"), a nationwide provider of clinical nutrition and specialty care services addressing complex needs for patients. Altemia™ is Lobe's proprietary formulation of emulsified docosahexaenoic acid ethyl ester ("DHA") concentration designed for patients with sickle cell disease ("SCD").

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results

- Seelos expects to release top-line data in two registrational studies in 2023

Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided a clinical update and reported its financial results for the first quarter ended March 31, 2023 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

-

Highlights:
  • COMP360 Phase 3 pivotal program underway, patients have been treated in both trials
  • CPT® III code for in-person psychedelic therapy support accepted by the American Medical Association
  • Cash position at 31 March 2023 of $117.1 million, additional $26.9 million net cash raised through ATM facility to date in the second quarter
  • Conference call today at 8:00am ET (1:00pm UK)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, reported its financial results for the first quarter 2023 and gave an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×